S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

Slides:

Advertisements

Similar presentations

Recent Emergency Study in Palestine Triage System At Al – Makassed Hospital Emergency Department Jamal Al-Wahadneh 2009.

Advertisements

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

10 Minutes Talk 吳華席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.

Aim To assess the effectiveness of medical or surgical treatment in patients with sino-nasal disease who present to ENT outpatient clinics.

Neoadjuvant Imatinib in DFSP SARC 004 University of Michigan coordinating center.

Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Brain imaging prior to lung cancer resection

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

From: Insidious Intoxication After Morphine Treatment in Renal Failure: Delayed Onset of Morphine-6-glucuronide Action Anesthes. 2000;92(5):1473. Figure.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

Volume 63, Issue 1, Pages (July 2015)

Volume 17, Issue 5, Pages (May 2016)

Fig year-old man with CLL and transformation to DLBCL. A

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis Karin Birkenkamp-Demtröder, Emil Christensen,

1st form Title Dentist Picture Content Content & Pictures

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

7.3c. Post-Contrast Axial CT of the Brain

Fig. S1 Diagram of experimental details as they occurred over the course of the two experiments from 0 to 50 days after sowing (18). Plants were grown.

Fig 1A. Patient enrollment flow chart

Director Department of Pediatric Hematology & Oncology Delhi, INDIA.

Suppl. Fig. 1 A B C No tumor - +

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

Table 1 Baseline patient characteristics

Learning About PET/CT Scans:

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

Updates in Hodgkin Lymphoma

Figure 3 Risk-adapted and response-adapted

Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

Volume 73, Issue 4, Pages (April 2018)

Bhandari et al. Am J Nephrol 2017;45: (DOI: / )

Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.

Consort Diagram 600 pts with 644 eyes accessed for eligibility

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

Successful Treatment with S-1 and Oxaliplatin Combination Therapy in an Elderly Patient with Metastatic Colorectal Cancer Initially Presenting with Membranous.

C.-P. Kuo, C.-L. Wu, H.-T. Ho, C.G. Chen, S.-I. Liu, Y.-T. Lu

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

Evaluation of viral co-infections in hospitalized and non-hospitalized children with respiratory infections using microarrays S. Kouni, P. Karakitsos,

EDLC(Embedded system Development Life Cycle ).

Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy F. M. Verduyn Lunel,

C. Agvald-öUhman, J. Wernerman, C.E. Nord, C. Edlund

Evaluation of a new 5'-nuclease real-time PCR assay targeting the Toxoplasma gondii AF genomic repeat J. Menotti, Y. J-F. Garin, P. Thulliez, M-C.

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study M.A.

W. van den Bijllaardt, I.T. Overdevest, A.G. Buiting, J.J. Verweij

Volume 147, Issue 2, Pages (November 2017)

The Role of Patients' Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane T. Hickok, MD, MPH, Joseph A. Roscoe,

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Diagnostic value of quantitative PCR for adenovirus detection in stool samples as compared with antigen detection and cell culture in haematopoietic stem.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Volume 63, Issue 1, Pages (July 2015)

C.2.10 Sample Questions.

C.2.8 Sample Questions.

A single centre experience of febrile neutropenia rates in long acting compared with short acting GCSF preparations in breast cancer patients Dr Rebecca.

Thing / Person:____________________ Dates:_________________

C.2.8 Sample Questions.

Consort Diagram 600 pts with 644 eyes accessed for eligibility

Aisling Krishnan, Yat Man Tsang, Adéle Stewart-Lord

Title Dentist Picture Content Content Content Content Content

Figure 1. Overview of BEECH study exploratory analysis

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Selection of DFU patients and non-DFU controls

Supplemental Fig 1 (A) (B) (B) 59% % alive 52% Years from entry 59%

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Duration of treatment and intervals of radiographic and ctDNA response

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

Presentation transcript:

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses of treatment for relapsed patients with ctDNA collected (54 courses, 32 patients) No pre-treatment sample (3 courses) Pre-treatment sample available (51 courses, 32 patients) More than 14 days from ctDNA date to start of treatment (1 course) ctDNA data pre-treatment available ≤14 days from start of treatment (50 courses, 32 patients) Non-measurable disease (1 course) Measurable disease by volumetric CT (49 courses, 32 patients) ctDNA change after first/second cycles ctDNA not detected pre-treatment (9 courses) ctDNA detected pre-treatment, at ≥20 AC/ml (40 courses, 27 patients) Non-evaluable for response, pre-treatment levels <40 AC/ml (2 courses) Pre-treatment levels ≥40 AC/ml (38 courses, 26 patients) ctDNA change after first cycle ctDNA change after second cycle (38 courses) No plasma samples before 2nd cycle of chemotherapy (6 courses) (38 courses) No plasma samples before 2nd cycle of chemotherapy (8 courses) Plasma samples available pre-cycle 2 (32 courses, 25 patients) Plasma samples available pre-cycle 2 (30 courses, 23 patients) Recent ascitic drain (7 courses) Recent ascitic drain (8 courses) No recent drain (25 courses, 20 patients) No recent drain (22 courses, 16 patients)